Current Osteoporosis Reports

, Volume 7, Issue 1, pp 23–26 | Cite as

Glucocorticoid-induced osteoporosis



Glucocorticoid treatment can alter bone metabolism, reduce bone strength, and increase the risk for osteoporotic fractures. Risk factors for glucocorticoid-induced osteoporosis (GIO) include older age, high doses, and longer duration of glucocorticoid use. The bone loss that accompanies glucocorticoid use is rapid, and early treatment with bone-sparing agents can prevent bone loss and reduce fracture risk. Several randomized controlled clinical trials have found prevention and treatment of GIO with bisphosphonates, and recently the treatment of GIO with teriparatide, to be effective. This article reviews current information on the epidemiology, pathophysiology, and clinical studies that support using bone-active agents to prevent and treat GIO.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Van Staa TP, Leufkens HG, Abenhaim L, et al.: Use of oral corticosteroids in the United Kingdom. QJM 2000, 93:105–111.PubMedCrossRefGoogle Scholar
  2. 2.
    Van Staa TP, Leufkens HG, Cooper C: The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002, 13:777–787.PubMedCrossRefGoogle Scholar
  3. 3.
    Van Staa TP, Leufkens HG, Abenhaim L, et al.: Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000, 15:993–1000.PubMedCrossRefGoogle Scholar
  4. 4.
    Van Staa TP, Leufkens HG, Abenhaim L, et al.: Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000, 39:1383–1389.CrossRefGoogle Scholar
  5. 5.
    Van Staa TP, Laan RF, Barton IP, et al.: Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003, 48:3224–3229.PubMedCrossRefGoogle Scholar
  6. 6.
    Kanis JA, Johansson H, Oden A, et al.: A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004, 19:893–899.PubMedCrossRefGoogle Scholar
  7. 7.
    Van Staa TP, Leufkens HG, Cooper C: Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001, 16:581–588.PubMedCrossRefGoogle Scholar
  8. 8.
    Wong CA, Walsh LJ, Smith CJ, et al.: Inhaled corticosteroid use and bone mineral density in asthma. Lancet 2000, 355:1399–1403.PubMedCrossRefGoogle Scholar
  9. 9.
    Herrala J, Puolijoki H, Impivaara O, et al.: Bone mineral density in asthmatic women on high-dose inhaled beclomethasone dipropionate. Bone 1994, 15:621–623.PubMedCrossRefGoogle Scholar
  10. 10.
    Ip M, Lam K, Yam L, et al.: Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids. Chest 1994, 105:1722–1727.PubMedCrossRefGoogle Scholar
  11. 11.
    Israel E, Banerjee TR, Fitzmaurice GM, et al.: Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001, 345:941–947.PubMedCrossRefGoogle Scholar
  12. 12.
    Geddes DM: Inhaled corticosteroids: benefits and risks. Thorax 1992, 47:404–407.PubMedCrossRefGoogle Scholar
  13. 13.
    Yao W, Cheng Z, Busse C, et al.: Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum 2008, 58:1674–1686.PubMedCrossRefGoogle Scholar
  14. 14.
    Dalle Carbonare L, Arlot ME, Chavassieux PM, et al.: Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 2001, 16:97–103.CrossRefGoogle Scholar
  15. 15.
    Manolagas SC: Corticosteroids and fractures: a close encounter of the third cell kind. J Bone Miner Res 2000, 15:1001–1005.PubMedCrossRefGoogle Scholar
  16. 16.
    Baron R, Rawadi G: Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007, 148:2635–2643.PubMedCrossRefGoogle Scholar
  17. 17.
    Ohnaka K, Tanabe M, Kawate H, et al.: Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 2005, 329:177–181.PubMedCrossRefGoogle Scholar
  18. 18.
    Lane NE, Yao W, Balooch M, et al.: Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res 2006, 21:466–476.PubMedCrossRefGoogle Scholar
  19. 19.
    Lane NE, Lukert B: The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am 1998, 27:465–483.PubMedCrossRefGoogle Scholar
  20. 20.
    Recommendations for the prevention and treatment of glucocorticoids-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoids-Induced Osteoporosis [no authors listed]. Arthritis Rheum 2001, 44:1496–1503.Google Scholar
  21. 21.
    Buckley LM, Leib ES, Cartularo KS, et al.: Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996, 125:961–968.PubMedGoogle Scholar
  22. 22.
    Adachi JD, Bensen WG, Bianchi F, et al.: Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year follow up. J Rheumatol 1996, 23:995–1000.PubMedGoogle Scholar
  23. 23.
    Reid IR, Wattie DJ, Evans MC, Stapleton JP: Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996, 156:1173–1177.PubMedCrossRefGoogle Scholar
  24. 24.
    Compston J, Reid DM, Boisdron J, et al.: Recommendations for the registration of agents and prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. Osteoporos Int 2008, 19:1247–1250.PubMedCrossRefGoogle Scholar
  25. 25.
    Saag KG, Emkey R, Schnitzer TJ, et al.: Alendronate for the prevention and treatment of glucocorticoids-induced osteoporosis. Glucocorticoids-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998, 339:292–299.PubMedCrossRefGoogle Scholar
  26. 26.
    Adachi JD, Saag KG, Delmas PD, et al.: Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001, 44:202–211.PubMedCrossRefGoogle Scholar
  27. 27.
    Reid DM, Hughes RA, Laan RF, et al.: Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 2000, 15:1006–1013.PubMedCrossRefGoogle Scholar
  28. 28.
    Cohen S, Levy RM, Keller M, et al.: Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999, 42:2309–2318.PubMedCrossRefGoogle Scholar
  29. 29.
    Luengo M, Pons F, Martinez de Osaba MJ, Picado C: Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoids therapy for asthma: a two year follow up study. Thorax 1994, 49:1099–1102.PubMedCrossRefGoogle Scholar
  30. 30.
    Montemurro L, Schiraldi G, Fraioli P, et al.: Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int 1991, 49:71–76.PubMedCrossRefGoogle Scholar
  31. 31.
    Reid DM, Devogelaer J, Saag K, et al.: Effect of a single infusion of zoledronic acid 5mg versus oral risedronate 5mg on bone mineral density at lumbar spine, hip, femoral neck and trochanter in patients with glucocorticoid induced osteoporosis [abstract F403]. J Bone Miner Res 2008, 23:s122.Google Scholar
  32. 32.
    Delmas P, Reid I, Rizzoli R, et al.: Bone mineral density and biochemical marker response rates in postmenopausal women after treatment with zoledronic acid [abstract F401]. J Bone Miner Res 2008, 23:s121.CrossRefGoogle Scholar
  33. 33.
    Saag KM, Zanchetta JR, Devogelaer J, et al.: Teriparatide versus alendronate for treatment of glucocorticoid induced osteoporosis: 36 month results [abstract 1171]. J Bone Miner Res 2008, 23:s49.Google Scholar
  34. 34.
    Saag K, Shane E, Boonen S, et al.: Teriparatide or alendronate in glucocorticoid induced osteoporosis. N Engl J Med 2007, 357:2028–2039.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  1. 1.Cedars-Sinai/UCLA and OMC Clinical Research CenterBeverly HillsUSA

Personalised recommendations